Digital Health Financing Weekly Report [Issue 170] Files for IPO
Kardium
Atrial Fibrillation Treatment Device Developer
Certify
Intelligent Platform Supplier
Mandolin
Drug Access AI Automation Platform
Field Medical
Developer of Pulsed Electric Field Catheter Ablation Technology
01 Global Digital Health Investment and Financing Overview
Atrial Fibrillation Treatment Device Developer Kardium Secures $250 Million in Financing
On July 2, atrial fibrillation treatment device developer Kardium secured $250 million in funding from new investors such as Janus Henderson Investors and Qatar Investment Authority, existing investors like T. Rowe Price Associates, and a strategic investor. The funds will primarily be used to advance global regulatory approval for the Globe system, expand production facilities to increase capacity, and build clinical support and commercial teams.
Certify, a Smart Authentication Platform for Healthcare Systems, Secures $40 Million in Series B Funding
On June 26, Certify, a smart authentication platform for the healthcare system, secured $40 million in Series B funding, led by Transformation Capital, with continued support from General Catalyst and Upfront Ventures, as well as new investment from SemperVirens. The funds will be used to accelerate product, engineering, and go-to-market efforts to meet growing market demand.
Mandolin, a drug access AI automation platform, secures $40 million in funding
On June 25, Mandolin, an AI automation platform for drug access, secured $40 million in funding from investors including Greylock Partners, SignalFire, Maverick, and SV Angel. The funds will be used to further develop its AI automation platform and optimize the process for accessing specialty drugs.
Pulsed Field Catheter Ablation Technology Developer Field Medical Secures $35 Million Series B Financing
On July 1, Field Medical, a developer of pulsed electric field catheter ablation technology, secured $35 million in Series B funding, co-led by BioStar Capital and Cue Growth, with participation from existing strategic investors. The funds will be used to advance the development of the FieldForce pulsed field ablation platform and initiate the pivotal VERITAS trial, enhancing the company’s clinical and regulatory capabilities.
Brain-Computer Interface Technology Wearable Device Developer Wispr Flow Raises $30 Million in Series A Funding
On June 25, Wispr Flow, a developer of wearable brain-computer interface technology, secured $30 million in Series A funding led by Menlo Ventures, with participation from notable investors such as Kenneth Schlenker and Evan Sharp. The funds will be used to expand its AI-driven voice input technology, further challenging traditional keyboard input methods.
Cancer Molecular Testing Provider Imagene AI Secures $23 Million in Series B Funding
On July 1, Imagene AI, a provider of molecular cancer testing, secured $23 million in Series B funding led by Larry Ellison, Chairman and CTO of Oracle, with participation from existing investor Aguras Pathology Investments. The funds will be used to advance its multimodal digital pathology foundational model for precision medicine, which has been trained on over 1.5 million biopsy images and is capable of processing histopathology images, molecular profiles, and clinical context.
Precision Microbiota Transplantation Solution Provider Chengge Bio Obtains Over 100 Million Yuan in Strategic Investment
On June 27, Chengge Bio, a provider of precision microbiota transplantation solutions, secured over RMB100 million in strategic investment led by Jinhé Capital. The proceeds will be used to deepen core platform technology, accelerate clinical research and registration, expand the layout of indications, improve the commercialization network, and strengthen the construction of bacterial libraries and databases.
Comprehensive Automation Solution Provider in Life Science Field, Zhongxi Bio, Secures Nearly RMB100 Million in Series A Funding
On July 1, Zonlink Bio, a provider of comprehensive automation solutions in the life sciences field, secured nearly RMB 100 million in its Series A financing round, led by CITIC Securities Investment with continued investment from Qiming Venture Partners. The funds will accelerate Zonlink Bio’s development and global promotion of its "intelligent ecosystem for full-process automation in life sciences," expanding its reach to empower a broader range of research and industrial applications.
Synthetic Biology Technology Researcher Rongrui Technology Secures Nearly RMB 100 Million in Pre-A Funding
On June 27, synthetic biotechnology researcher Rongrui Technology secured nearly RMB 100 million in Pre-A funding, jointly led by PuHua Capital and CDH VGC (Venture & Growth Fund). The proceeds from this round of financing will be mainly used to accelerate the development of the company’s product pipeline, as well as to continuously advance industrialization and commercialization processes.
Mental Health Service Provider Handspring Raises $12 Million in Series A Funding
On July 2, mental health service provider Handspring secured $12 million in Series A funding, led by Cobalt Ventures with participation from NextView Ventures, nvp capital, and others. The funds will be used to strengthen its proprietary technology platform and further develop artificial intelligence tools focused on automated operations and improved care outcomes.
Digital Health Platform Elfie Secures $12 Million in Series A Funding
On June 25, digital health platform Elfie secured $12 million in Series A funding, led by White Star Capital with participation from LifeX Ventures. The funds will be used to accelerate user acquisition, expand the team, and launch Elfie Research, a decentralized clinical trial platform aimed at generating real-world evidence and supporting clinical innovation.
Escala Medical, a developer of medical devices for the treatment of women's pelvic organ prolapse, secures €4.5 million in funding
On July 1, Escala Medical, a developer of medical devices for the treatment of women's pelvic organ prolapse, secured €4.5 million in funding, including a €2.5 million grant from the European Innovation Council (EIC) and additional funds from undisclosed U.S. and Israeli investors. This round of financing will be used to advance the ongoing commercialization efforts of its Mendit device in the U.S. and support plans for the device’s entry into the European market, which is currently awaiting CE mark approval.
Healthcare Software Developer LogicFlo Secures $2.7 Million in Seed Funding
On June 30, healthcare software developer LogicFlo secured $2.7 million in seed funding, led by Lightspeed. This round of financing will be used to expand its intelligent agent platform into the pharmaceutical, biotechnology, and medical technology industries, equipping each life science expert with their own AI workforce and transforming them into leaders of their own workflows.
AI-Driven Clinical Intelligence Platform Nephrolytics Secures $2.5 Million in Funding
On June 25, AI-driven clinical intelligence platform Nephrolytics secured $2.5 million in funding. This round of financing will be used to accelerate product development, expand the customer success team, and support rapid adoption across kidney disease clinics and large dialysis organizations in China.
CorNav Collaborates with Mayo Clinic to Develop New Treatments for Ventricular Tachycardia
On July 1, CorNav partnered with Mayo Clinic to develop a new minimally invasive targeted treatment for ventricular tachycardia (VT). This collaboration aims to advance the treatment of VT patients who do not respond to medication. CorNav's CardioScout™ epicardial access system, through a minimally invasive endoscopic platform, provides real-time, high-fidelity color video imaging covering the epicardial surface of the beating heart, enabling precise navigation to the target area. It is expected to make epicardial ventricular tachycardia ablation procedures safer, more efficient, and more effective.
Medtronic and Philips Establish Strategic Partnership to Expand the Use of Patient Monitoring Technologies
On July 1, Medtronic and Philips signed a multi-year partnership agreement aimed at improving patient care and expanding access to technology. This collaboration integrates Medtronic's next-generation technologies into Philips' monitoring solutions, providing simplified services for healthcare providers. Philips’ patient monitoring systems currently incorporate Medtronic’s Nellcor™ pulse oximetry, Microstream™ capnography, and BIS™ brain monitoring technologies.
Aier Eye Hospital and Huawei Cloud Sign Strategic Cooperation Agreement to Advance "AI + Ophthalmology" Integrated Development
On June 28, Aier Eye Hospital Group and Huawei Cloud reached an artificial intelligence strategic cooperation agreement, focusing on several key areas including Aier's AI planning, the expansion of ophthalmology AI large model application scenarios, and AI infrastructure. The two parties will work together to carry out in-depth cooperation in the field of artificial intelligence for eye health, jointly promote the development of smart healthcare for eye health, and create a compassionate AI-powered smart ophthalmology hospital.
Medical Technology Provider Teleflex Acquires BIOTRONIK Vascular Intervention Business for 760 Million Euros
On July 2, medical technology provider Teleflex acquired BIOTRONIK's vascular intervention business for 760 million euros. BIOTRONIK is a developer of rhythm management and vascular intervention medical technologies. This acquisition adds a broad therapeutic product portfolio to Teleflex's interventional access product offerings. The acquired vascular intervention business includes a comprehensive and differentiated product portfolio for coronary and peripheral interventions, with key products such as the Pantera™ Lux™ drug-coated balloon catheter and the PK Papyrus™ covered coronary stent.
Siemens Acquires Dotmatics for $5.1 Billion
On July 1, Siemens acquired Dotmatics for $5.1 billion. Dotmatics is a scientific software service provider. This acquisition strengthens Siemens' position as a global leader in AI-driven PLM software and enables Siemens to expand its technology into the life sciences field to fully seize growth opportunities. Dotmatics' scientific intelligence platform, Luma, along with its industry-leading scientific applications, make multimodal drug development, seamless collaboration, and contextual data creation possible, spanning an interconnected digital thread across the value chain from R&D to production.
Danone, a provider in the food and nutrition sector, acquires Kite Farm
On July 1, Danone, a provider in the food and nutrition sector, acquired Kate Farms, an American plant-based, organic nutritional formula provider dedicated to better serving patients with medical needs and individuals seeking daily nutritional support. This acquisition marks Kate Farms' further expansion into the plant-based clinical nutrition field and becomes part of Danone's North American medical nutrition business.
Xinhanglu Medicine Acquires Core Assets of Acutus Medical's AcQMap™ High-Resolution Imaging and Mapping Platform
On June 30, Epios Medical, the leading innovator in cardiac electrophysiology, acquired the core assets of Acutus Medical's AcQMap™ high-resolution imaging and mapping platform, a developer of endocardial imaging systems. This transaction not only includes intellectual property, technical documentation, clinical data, and equipment but also signifies that the development of non-contact mapping technology has entered a new phase of integration.
Healthcare Solutions Provider Premier Acquires IllumiCare
On June 30, healthcare solutions provider Premier acquired IllumiCare, a medical technology company known for its Electronic Medical Record (EMR)-agnostic platform. This strategic move significantly expands Premier's capabilities in the Clinical Decision Support (CDS) field by integrating IllumiCare's real-time clinical and financial data at the point of care. IllumiCare’s flagship product assists healthcare providers in making better clinical decisions by delivering real-time data on treatment costs directly to them.
In Vitro Diagnostics Developer Fujirebio Acquires Plasma Services Group
On June 26, in vitro diagnostic product developer Fujirebio acquired Plasma Services Group (PSG), a supplier of hard-to-obtain biological materials in the life science field. Through this collaboration, Fujirebio and PSG's existing and future partners will gain access to a richer pool of scarce samples and biological materials, further solidifying Fujirebio’s market position.
Artery Network/Artery Orange Industry Think Tank/Huaxing Capital/BGI Co-Win/Rock Health/Mobile Health News/FierceHealth, etc.'%20fill='%23FFFFFF'%3E%3Crect%20x='249'%20y='126'%20width='1'%20height='1'%3E%3C/rect%3E%3C/g%3E%3C/g%3E%3C/svg%3E)
Share
Like
Tap to view